AnaptysBio Inc (NASDAQ:ANAB) has been assigned an average rating of “Buy” from the twelve brokerages that are covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and nine have issued a buy recommendation on the company. The average 12-month price objective among brokerages […]
